Exclusive Rights Secured for Domestic Development and Commercialization

JW Pharmaceutical announced on April 9, 2026 that it has signed an exclusive license-in (technology introduction) agreement with Qiananli Pharmaceuticals (Qiananli), a Beijing-based pharmaceutical company, for the domestic rights to the new GLP-1 (glucagon-like peptide-1) receptor agonist drug candidate, Bofanglutide.


Through this agreement, JW Pharmaceutical has secured exclusive rights to the development, approval, marketing, and commercialization of Bofanglutide in South Korea. Qiananli will provide regulatory data necessary for clinical trial application (IND) approval and product registration in Korea and cooperate in related work.


Lee Kyungha, Chairman of JW (right), and Wei Chen, Chairman of Qiananli Pharmaceuticals, are taking a commemorative photo after signing the contract. JW Pharmaceutical Co., Ltd.

Lee Kyungha, Chairman of JW (right), and Wei Chen, Chairman of Qiananli Pharmaceuticals, are taking a commemorative photo after signing the contract. JW Pharmaceutical Co., Ltd.

View original image

Introducing a New Obesity Drug Administered Once Every Two Weeks

JW Pharmaceutical will pay Qiananli an upfront payment of USD 5 million (approximately KRW 7.4 billion) and milestone payments totaling USD 76.1 million (approximately KRW 112.7 billion), bringing the total contract value to USD 81.1 million (approximately KRW 120.1 billion). The milestone payments include development, approval, and sales milestones for four indications: type 2 diabetes, obesity, obstructive sleep apnea (OSA), and MASH (metabolic dysfunction-associated steatohepatitis). Royalties will be paid separately based on sales tiers.


Bofanglutide is a synthetic peptide new drug currently being developed as a GLP-1 receptor agonist administered subcutaneously (SC) once every two weeks. The drug works by acting on GLP-1 receptors in the pancreas to stimulate insulin secretion and regulate blood glucose levels, while also delaying gastric emptying to prolong the feeling of fullness. Through these mechanisms, it suppresses appetite and promotes weight loss, targeting indications such as diabetes, obesity, sleep apnea, and MASH.


Bofanglutide, currently in Phase 3 clinical trials in China, has demonstrated superior convenience and efficacy compared to existing therapies. In a Phase 2b clinical trial for the obesity indication, the drug resulted in an average weight loss of 17.29% over 30 weeks with biweekly administration. Notably, compared to clinical data for existing once-weekly products, Bofanglutide delivered outstanding weight loss and glycemic control even within a relatively shorter dosing period, showing its potential as a next-generation obesity treatment.


Bofanglutide has also received approval from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for chronic weight management. Currently, a Phase 2 trial is underway in the United States, directly comparing Bofanglutide with placebo and tirzepatide in overweight or obese patients.


JW Pharmaceutical expects that Bofanglutide will gain a competitive edge in the current GLP-1 market, where once-weekly administration is the norm, by offering "dosing convenience" as a key differentiator. The company aims to respond proactively to the rapidly growing metabolic disease treatment market by quickly introducing a drug candidate that has already made significant progress in clinical development.

Chairman Kyungha Lee of JW and Chairman Wei Chen of Qiananli Pharmaceuticals, along with executives and employees from both companies, are taking a commemorative photo. JW JoongWai Pharmaceutical

Chairman Kyungha Lee of JW and Chairman Wei Chen of Qiananli Pharmaceuticals, along with executives and employees from both companies, are taking a commemorative photo. JW JoongWai Pharmaceutical

View original image

Domestic Phase 3 Clinical Trials Planned for the Second Half of This Year

JW Pharmaceutical has not only focused on its own innovative drug research and development, but has also successfully introduced promising overseas new drugs such as "Livaro" for hyperlipidemia, "Actemra" for rheumatoid arthritis, and "Hemlibra" for hemophilia into the Korean market. This agreement is an extension of its "license-in" strategy and is expected to further strengthen its portfolio of original specialty drugs in the metabolic disease field.


JW Pharmaceutical plans to simultaneously conduct domestic Phase 3 clinical trials for the obesity and type 2 diabetes indications of Bofanglutide in the second half of this year.


Shin Youngseop, CEO of JW Pharmaceutical, stated, "Through this agreement, we have expanded our portfolio in the rapidly growing field of metabolic diseases, centered on diabetes and obesity. Based on JW's proven capabilities in development and regulatory approval, we will successfully commercialize Bofanglutide in Korea and provide patients with innovative treatment options."



Li Zhi, Chief Business Officer (CBO) of Qiananli Pharmaceuticals, said, "We are pleased to establish a foundation for the development and commercialization of Bofanglutide in the Korean market through our collaboration with JW Pharmaceutical. Both companies will work closely together to provide Korean patients with new treatment options for metabolic diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing